AroCell AB: TK 210 ELISA abstract on in-vitro studies of cancer drugs has been accepted for presentation at the National Canc...
September 22 2017 - 5:30AM
AroCell AB (publ) announces today
that an abstract submitted Kiran Kumar Jagarlamudi et al entitled
"The AroCell TK 210 ELISA provides new information concerning the
mechanism of anti-cancer drugs by determining the TK1 protein
levels in cultured cells in vitro" was accepted by the NCRI for
presentation at their annual meeting in Liverpool, November 5-8,
2017.
The purpose of this study was to evaluate the
capacity of TK 210 ELISA to measure TK1 levels in tumor cell
culture models, using CEM lymphoblastic cells and Doxorubicin,
which is an effective anti-neoplastic drug for both hematological
and solid malignancies, and a commonly used chemotherapy drug. The
conclusion in the study is that use of AroCell TK 210 ELISA
provides opportunities for in-vitro studies of old and new
anti-cancer drugs, targeting cell proliferation, which may assist
in the development of new therapeutic agents.
"We are delighted over the results in this study
and it is another piece of evidence that TK 210 ELISA will have a
very broad applicability also in early stage drug development"
states Jan Stålemark, CEO. "Controlling and/or inhibiting cell
proliferation is an important parameter in early drug development
and thus in the selection of drug candidates for cancer therapy.
However, there are few cell-proliferation biomarkers which are
suitable for large-scale use in in-vitro studies. This present work
shows that TK1 levels in-vitro can be used to gain information on
the effects of anti-cancer agents with tumor derived model cell
lines. Furthermore, measuring the serum TK1 levels in patients with
the TK 210 ELISA has been shown to provide clinically valuable
information in a range of malignancies. This means that the assay
of TK1 with the AroCell TK 210 ELISA test has the potential to
enable routine application to drug discovery studies and in
clinical trials. This potential is reinforced by another recent
abstract on cell culture entitled Doxorubicin
effects on leukemia and breast cancer cells in culture on
the TK1 protein levels using AroCell TK 210 ELISA: a tool for drug
development" says Jan Stålemark.
For additional
information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706926206
info@arocell.com
www.arocell.com
This information is information
that AroCell is obliged to make public pursuant to the EU Market
Abuse Regulation and the Securities Markets Act. The information
was submitted for publication, through Jan Stålemark, at 11.30 CET
on 22 September 2017.
About AroCell
AroCell AB (AROC) is a Swedish
company that develops standardized modern blood tests to support
the prognosis and follow up of cancer patients. AroCell's new
technology is based on patented methods to measure TK1 protein
levels, which provide valuable information about the rate of cell
turnover. A tumor has high cell turnover (rate of cell division and
cell death) and as a result TK1 can be detected in the blood with a
simple laboratory test, called TK 210 ELISA. The test provides
valuable clinical information for prognosis and optimization of
treatment strategies. The test may also be used for monitoring
disease relapse. AroCell (AROC) is listed at Nasdaq First North and
has about 2,500 shareholders. For more information, please see
www.arocell.com. Redeye AB is AroCell:s Certified Adviser.
AroCell press release Sept 22,
2017
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: AroCell AB via Globenewswire
Archrock (NYSE:AROC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Archrock (NYSE:AROC)
Historical Stock Chart
From Sep 2023 to Sep 2024